MannKind Corporation (MNKD) And Sanofi SA (ADR) (SNY)’s Strategic Partnership

Posted by Lynn Eisler January 2, 2015 0 Comment 2173 views

MannKind Corporation (NASDAQ:MNKD) have pulled up its marketing gimmicks to ensure that it remains a strong contender in the rat race and lure investors in large numbers. Lately, it has gained an approval for rolling out the rampant sales after manufacturing of insulin Afrezza, from FDA. There have been tough times of cajoling as a plenitude of attempts needed to be done to seek the permission of legal sale out.

Moreover, the biotech giant has set up a mutually benefiting association or partnership with another stellar company Sanofi SA (ADR) (NYSE:SNY) for robust and strategically sound marketing of the drugs being manufactured. At the current premise, and a plethora of projects in line for permissions and rollout, 2015 is deemed to emerge as a watershed year for holistic development, profits, and sumptuous returns over a longer term in near future.

Not Profound, But Prolonged Sales Likely

Profound sales are not projected, neither estimated nor expected. In order to be recognized amongst the top drawn shares and top the expectations’ lists for traders, MannKind Corporation (NASDAQ:MNKD) have to perform outstandingly well. Afrezza is got to be high on sales; however, MNKD owns merely 35% of this drug. However, in all likelihoods, MannKind Corporation (NASDAQ:MNKD) has no chance of making profits exceeding expectations, as the company has a meager P/S value at around five!

The Exubera Example

The best case scenario is that the company would have sumptuous sales and proceeds, only if the net Afrezza sales would cross the psychological $500 million mark! This figure seems inappropriate or sky high, because on a comparative note, Pfizer Inc. (NYSE:PFE) managed to procure merely $12 million by rampant sales of the product called Exubera.

Afrezza Expects Moderate Sellout

It may not carry the dub of the best insulin till date, however, Afrezza is seemingly far easier to inject and adopt readily than any other insulin drug. With not many potential or hazardous issues pertaining to Afrezza propping up, chances of widespread sales are high. Thus, it is indeed the perfect time to purchase the stock, as it is deemed to rise in near future.

About Lynn Eisler

Lynn Eisler is a national news reporter focusing on economic issues, data analysis and the financial health of state and local governments. Lynn has been honored with the H.L. Mencken Award for Investigative Reporting, the Champion of Justice Award for reporting on the drug war, and the John Hancock Award for business reporting. Lynn was also a Knight Medical School Fellow at the University of Michigan.

View all post by Lynn Eisler Visit author's website

Write Your Comment